Virax Biolabs GroupVRAX
13F holders, Q1 2024 (March 31)3holders
1famous investor
$0.72avg. 13F price*
At the end of Q1 2024, 3 institutions reported holding Virax Biolabs Group Ltd. (VRAX) in their 13F filings. The largest holders were Citadel Advisors ($11K), UBS Group AG ($2K) and Wells Fargo & Company ($72). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Virax Biolabs Group Ltd.
- CUSIP
- G9495L125
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $11K |
| Exits | 2 | $194K |
Ownership 3 holders
| Citadel Advisors | 0.00% | New | 14,785 | $11K |
| UBS Group AG | 0.00% | Add +287.2% | 2,575 | $2K |
| Wells Fargo & Company | 0.00% | Reduce -50.0% | 100 | $72 |
"% of holder's portfolio" is VRAX's weight in each manager's 13F, not the share of Virax Biolabs Group Ltd. the manager owns.